A5014977921- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Vaccine Coverage and Hesitancy
- Hormonal Regulation and Hypertension
- vaccines and immunoinformatics approaches
- HIV Research and Treatment
- HIV/AIDS drug development and treatment
- Blood Pressure and Hypertension Studies
- Pneumocystis jirovecii pneumonia detection and treatment
- Sepsis Diagnosis and Treatment
- Immunotherapy and Immune Responses
- COVID-19 and Mental Health
- Trauma and Emergency Care Studies
- Viral Infections and Outbreaks Research
- Parasitic Diseases Research and Treatment
- HIV/AIDS Research and Interventions
- Disaster Response and Management
- Sodium Intake and Health
- Pneumonia and Respiratory Infections
- Long-Term Effects of COVID-19
- Respiratory viral infections research
Soweto CTC
2010-2024
University of the Witwatersrand
2021
Right to Care
2015
GTx (United States)
2015
Impact
2010
Daiichi Sankyo (United States)
2010
Assessment of the safety and efficacy vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in different populations is essential, as investigation emerging SARS-CoV-2 variants concern, including B.1.351 (501Y.V2) variant first identified South Africa.
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants threatens progress toward control the disease 2019 (Covid-19) pandemic. In a phase 1–2 trial involving healthy adults, NVX-CoV2373 nanoparticle vaccine had an acceptable safety profile and was associated with strong neutralizing-antibody antigen-specific polyfunctional CD4+ T-cell responses. Evaluation efficacy needed in setting ongoing SARS-CoV-2 transmission.
Abstract Background Assessing safety and efficacy of Covid-19 vaccines in different populations is essential, as investigation against emerging SARS-CoV-2 variants concern including the B.1.351 (501Y.V2) variant first identified South Africa. Methods We conducted a randomized multicentre, double blinded controlled trial on ChAdOx1-nCoV19 HIV-uninfected people Participants age 18 to <65 years (1:1) two doses vaccine containing 5×10 10 viral particles or placebo (0.9%NaCl) 21-35 days apart....
There is a paucity of data on COVID-19 vaccines in people living with HIV-1, who could be at increased risk severe illness and death from COVID-19. We evaluated the safety immunogenicity Matrix-M adjuvanted recombinant spike protein nanoparticle vaccine (NVX-CoV2373; Novavax) HIV-negative HIV-1.In this randomised, observer-blinded, multicentre, placebo-controlled phase 2A/B trial South Africa, participants aged 18-84 years, without underlying were enrolled 16 sites randomly assigned (1:1) to...
ABSTRACT Background The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants threatens progress toward control the Covid-19 pandemic. Evaluation vaccine efficacy against SARS-CoV-2 is urgently needed to inform development and use. Methods In this phase 2a/b, multicenter, randomized, observer-blinded, placebo-controlled trial in South Africa, healthy human immunodeficiency virus (HIV)-negative adults (18 84 years) or medically stable people living with HIV (PLWH)...
Objective: Immunocompromised individuals are at an increased risk of pneumococcal disease. Vaccination is recommended as important strategy to reduce disease in HIV-infected individuals. This study evaluated the safety and immunogenicity three 13-valent conjugate vaccine (PCV13) doses followed by one dose 23-valent polysaccharide (PPSV23) 1-month intervals vaccine-naive, Design: was a phase 3, open-label, single-arm study. Methods: Pneumococcal least 6 years age with CD4+ T-cell count 200...
BackgroundCOVID-19 vaccine rollout is lagging in Africa, where there has been a high rate of SARS-CoV-2 infection. We aimed to evaluate the effect infection before vaccination with ChAdOx-nCoV19 (AZD1222) on antibody responses through 180 days.MethodsWe did an unmasked post-hoc immunogenicity analysis after first and second doses AZD1222 randomised, placebo-controlled, phase 1b–2a study done seven locations South Africa. recipients who were HIV-uninfected, stratified into baseline...
The current study investigated the efficacy and safety of olmesartan medoxomil in children with hypertension, defined as systolic blood pressure measured at or above 95th percentile (90th for patients diabetes, glomerular kidney disease, family history hypertension) age, gender, height while off any antihypertensive medication. active treatment phase was conducted 2 periods, cohorts each period (cohort A, 62% white; cohort B, 100% Black). In 1, stratified by weight received low-dose (2.5 5...
Introduction In DUET, etravirine (ETR) 200 mg bid had durable efficacy and a favourable safety profile versus placebo, both arms with an optimised background regimen (BR) including darunavir/ritonavir (DRV/r). TMC125IFD3002 (VIOLIN; NCT01422330) investigated ETR plus ARVs other than DRV/r. Materials Methods This was 48 week, Phase IV, open‐label, single‐arm, multicentre study. HIV‐1‐infected treatment‐experienced adult patients on=8 weeks ARV therapy prior to screening, switching either for...
COVID-19 remains a global public health issue and an improved understanding of vaccine performance in immunocompromised individuals, including people living with HIV (PLWH), is needed. Initial data from the present study's pre-crossover/booster phase were previously reported. This 2a/b clinical trial South Africa (2019nCoV-501/NCT04533399) revisits 1:1 randomly assigned HIV-negative adults (18-84 years) medically stable PLWH (18-64 who received two NVX-CoV2373 doses (5 μg recombinant Spike...
VIOLIN (TMC125IFD3002; NCT01422330) evaluated the safety, tolerability, and pharmacokinetics of etravirine with antiretrovirals other than darunavir/ritonavir in HIV-1-infected patients.In a 48-week, phase IV, single-arm, multicenter study, patients on prior antiretroviral therapy (⩾8 weeks) who needed to change regimen for virologic failure (viral load ⩾ 500 copies/mL) or simplification/adverse events < 50 received 200 mg bid ⩾1 active antiretroviral, excluding only nucleoside/tide reverse...
Some South African (SA) healthcare practitioners are promoting the prescription and use of products claiming to contain ivermectin for treatment and/or prevention COVID-19 in SA. This study qualitatively analysed seven samples formulations (5 tablet 2 capsule formulations) being sold SA human use. The were using a high-performance liquid chromatography instrument connected Sciex X500R quadrupole time-of-flight high-resolution mass spectrometer. found that all had both major homologues (B1a...
Background: Covid-19 vaccine rollout is lagging in Africa, where there has been a high force of SARS-CoV-2 infection. We evaluated the effect infection prior to vaccination with ChAdOx-nCoV19 (AZD1222) on antibody responses through 180 days (D180).Methods: undertook post-hoc immunogenicity analysis after two doses AZD1222 randomised, placebo-controlled phase Ib/2a study undertaken South Africa. Recipients were stratified by serological assessment 1st dose into baseline seropositive or...